Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.1%

13 terminated/withdrawn out of 92 trials

Success Rate

81.2%

-5.3% vs industry average

Late-Stage Pipeline

29%

27 trials in Phase 3/4

Results Transparency

71%

40 of 56 completed trials have results

Key Signals

15 recruiting40 with results9 terminated4 withdrawn

Enrollment Performance

Analytics

Phase 2

38(42.7%)

Phase 1

23(25.8%)

Phase 3

22(24.7%)

Phase 4

5(5.6%)

N/A

1(1.1%)

89Total

Phase 2(38)

Phase 1(23)

Phase 3(22)

Phase 4(5)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (92)

Showing 20 of 92 trials

NCT07105111Phase 4Recruiting

A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

Role: lead

NCT07111988Phase 2Not Yet Recruiting

Valbenazine in Obsessive Compulsive Disorder

Role: collaborator

NCT05206513Phase 3Completed

Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy

Role: lead

NCT07365462Phase 2Recruiting

Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia

Role: lead

NCT06966401Phase 3Recruiting

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Role: lead

NCT07536269Phase 2Not Yet Recruiting

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old

Role: lead

NCT07288333Phase 2Recruiting

Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia

Role: lead

NCT07105098Phase 3Recruiting

NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

Role: lead

NCT07227818Phase 3Recruiting

Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia

Role: lead

NCT07114874Phase 3Recruiting

NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

Role: lead

NCT06963021Phase 3Recruiting

NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Role: lead

NCT06312189Phase 3Enrolling By Invitation

Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada

Role: lead

NCT07288320Phase 2Recruiting

An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania

Role: lead

NCT07187375Phase 2Recruiting

Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old

Role: lead

NCT07196501Phase 3Recruiting

A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Role: lead

NCT06963034Phase 3Recruiting

NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

Role: lead

NCT05301894Phase 2Terminated

Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep

Role: lead

NCT05110157Phase 3Completed

Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia

Role: lead

NCT05207085Phase 2Recruiting

Efficacy of Valbenazine for the Treatment of Trichotillomania in Adults

Role: collaborator

NCT05859698Phase 4Completed

Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia

Role: lead